Introduction
In breast cancer, current endocrine therapy offers substantial potential benefit in terms of reduction in risk of tumour recurrence and death in women with oestrogen receptor (ER) positive tumours. Although many women are initially responsive to endocrine therapy, approximately 30-40% will acquire resistance and relapse within 5 years of treatment. There is growing evidence to suggest that growth factor signalling pathways, their downstream effectors and regulators are central to the development of endocrine resistance (Cui et al., 2006) . Studies have found that cells with significantly increased levels of MAP kinase associate with resistance to endocrine manipulation (Hutcheson et al., 2003; Nicholson et al., 2004) .
Increased significance of growth factor pathways in the development of the resistant phenotype has instigated intense investigation into the influence of these signalling cascades. Ets proteins are a family of MAP kinase-dependent transcription factors, which have been implicated as downstream effectors of HER2 signalling (Galang et al., 1996) . In line with this, at a clinical level Ets proteins have been shown to associate with breast tumour disease progression and metastasis (Shepherd and Hassell, 2001 ). Recently we have described strong associations between Ets-1, and in particular Ets-2, and reduced disease-free survival on endocrine treatment (Myers et al., 2005) . The mechanisms of how Ets proteins mediate this resistance remain unclear.
There is now evidence to suggest that the ER target gene myc is also regulated by Ets-2 through E2F binding motifs in its promoter region (Roussel et al., 1994; Carbone et al., 2004) . Myc, itself a transcription regulator, plays an essential role in the control of cell proliferation, growth, differentiation and apoptosis (Grandori et al., 2000) . Of interest, in vitro studies have suggested a role for c-Myc in the development of endocrine resistance (McNeil et al., 2006) . It is possible therefore that as the tumour develops steroid independence, growth factor activation of Ets-2 could promote cell survival and disease progression by signalling through the proto-oncogene myc.
Ets transcription factors are now known to bind coregulatory proteins to modulate their transcriptional regulatory properties. Ets-1, -2 and the PEA3 family member, ER81 have been shown to recruit the transcription adaptor proteins p300 and CBP (Yang et al., 1998; Jayaraman et al., 1999; Papoutsopoulou and Janknecht, 2000; Foulds et al., 2004) . More recently we have proposed that the steroid receptor coactivator, p160 protein, SRC-1 is a functional coactivator of Ets-2. At a clinical level we have observed that expression of SRC-1 has a significant impact on Ets-2 mediated endocrine resistance (Myers et al., 2005) .
Here we use molecular and translational strategies to investigate Ets-2 activation of myc in endocrine resistant breast cancer and to assess the impact of the p160 proteins SRC-1 and SRC-3 on this regulation.
Results
Growth factor regulation of Ets-2 and c-Myc in endocrine resistant/insensitive breast cancer cells Ets-2 protein levels were upregulated in both endocrine resistant (LY2) and endocrine insensitive (SKBR3) breast cancer cells in the presence of epithelial growth factor (EGF) in comparison to untreated controls. No alteration in expression of Ets-1 in SKBR3 cells was observed. The growth factor induced a concomitant elevation in protein levels of c-Myc. However, in the endocrine sensitive cells (MCF7) and in the steroid independent, but endocrine treatment responsive (LCC1) breast cancer cells, EGF failed to substantially regulate protein expression of either Ets-2 or c-Myc (Figure 1 ).
Ets-2 transcriptionally regulates myc expression in endocrine resistant and insensitive breast cancer cells
The ability of Ets to bind to the myc promoter at E2F binding sites has previously been described by others (Roussel et al., 1994) . To investigate if Ets-2 can be recruited to the endogenous myc promoter in endocrine insensitive breast cancer cells, chromatin immunoprecipitation (ChIP) analysis was carried out. Chromatins from growth factor treated and untreated SKBR3 cells were immunoprecipitated with antibodies against Ets-2 and acetylated histone H4. The resultant DNA was then amplified using primers flanking the Ets-2 response element in the myc promoter. Very little binding was detected in the untreated cells, however treatment with EGF induced Ets-2 binding to the myc promoter (Figure 2a) . Consistent with gene activation in the presence of growth factors, acetylated histone H4 was detected at the myc promoter (Figure 2a ). These observations are consistent with the premise that growth factor mediated expression of c-Myc involves recruitment of Ets-2 to its response element in the myc promoter.
To elucidate the ability of Ets-2 to transcriptionally activate myc expression we undertook luciferase reporter assays. An oligo specific for the myc promoter and containing the Ets response element was cloned into the pGL3-promoter vector (pGL3-myc promoter). Exogenous Ets-2, but not Ets-1, increased the enhancer activity of the myc promoter in the endocrine insensitive (SKBR3) breast cancer cells (Figure 2b ). EGF alone increased myc promoter activity and EGF in the presence of exogenous Ets-2 enhanced myc transcriptional activity compared with either exogenous Ets-2 or growth factor treatment alone (Figure 2b) . We looked at the ability of Ets-2 to differentially modulate the transcriptional activity of myc in endocrine sensitive versus endocrine resistant/insensitive breast cancer cells. Ets-2 alone and in the presence of EGF transcriptionally activated myc in the endocrine resistant LY2 cells and in Figure 2c ). However, exogenous Ets-2 in the presence of EGF resulted in higher myc transcriptional activity compared with EGF alone. To determine if Ets-2 can control c-Myc protein expression, Ets-2 was transiently transfected into LY2 and SKBR3 breast cancer cells alone and in the presence of EGF. An increase in c-Myc expression was observed in the presence of exogenous Ets-2. Though increases in both Ets-2 and c-Myc expression were noted with EGF in cells transfected with the pCGN backbone, no further increase in c-Myc protein expression was observed in cells transfected with pCGN-Ets-2, probably due to saturation of the cells overexpressing Ets-2. To confirm the relationship between Ets-2 and c-Myc, Ets-2 protein expression was knocked down following transfection with siRNA specific for Ets-2 and a corresponding decrease in c-Myc protein levels was detected (Figure 2d ). No alteration in expression of c-Myc was observed in SKBR3 cells in the presence of exogenous Ets-1 (Figure 2d ).
To assess the specificity of Ets-2 transcriptional activation of myc, we transfected SKBR3 cells with wild-type Ets-2 or Ets-2 (T72A), a threonine 72 to alanine mutation which impairs MAP kinase induced Ets-2 transcriptional activity (Yang et al., 1996) . Overexpression of wild-type Ets-2, but not Ets-2 (T72A), upregulated myc transcripts as determined by (RT) reverse transcriptase-PCR (Figure 2e ).
Silencing of p160 genes results in loss of Ets-2 transcriptional activity The role of the p160 coactivator proteins SRC-1 and SRC-3 in Ets-2 transcriptional activation of myc was examined. As there is no evidence from the literature of a role for SRC-2 in breast tumour progression or more specifically in endocrine resistance, this p160 protein was not included in this study. siRNA was used to suppress protein expression of SRC-1. No alteration in Ets-2 expression was observed; however, a concomitant decrease in c-Myc protein expression was detected in both the endocrine resistant LY2 and endocrine insensitive SKBR3 cells (Figure 3a) . Silencing of SRC-1 inhibited EGF-induced myc promoter activity in both the LY2 and SKBR3 cells. Moreover, knock down of SRC-1 also abrogated increased myc transcriptional activity due to exogenous Ets-2 ( Figure 3b ). In contrast to SRC-1, silencing SRC-3 reduced Ets-2 protein expression. Knock down of SRC-3 also resulted in reduced c-Myc protein expression ( Figure 3c ) and suppressed EGF-and Ets-2-induced myc transcriptional activity ( Figure 3d ). Furthermore, knock down of Ets-2, SRC-1 or SRC-3 resulted in depletion of EGF-induced myc mRNA levels ( Figure 3e ).
Knock down of Ets-2 SRC-1 and SRC-3 induces apoptosis in endocrine resistant and insensitive breast cancer cells
The growth factor EGF reduced apoptosis in SKBR3 cells, though no substantial decrease was noted in LY2 cells. Silencing of Ets-2, SRC-1 and SRC-3 induced apoptosis in SK-BR-3 and LY2 cells . Treatment with EGF did not affect increased apoptosis observed due to knock down of the transcription factor and coactivator proteins.
Localization and expression of Ets-2, c-Myc, SRC-1 and SRC-3 in patients with locally advanced breast cancer Strong positive staining for Ets-2 and c-Myc was detected in the nuclei of breast tumour epithelial cells and to a lesser extent within the cytoplasm (Figure 5a ). Using immunofluorescence, co-expression of Ets-2 with c-Myc was observed in breast cancer epithelial cells (Figure 5b ).
Expression of Ets-2, p160 proteins and c-Myc was assessed in a small cohort of breast cancer patients with locally advanced disease treated with endocrine and chemotherapy in a neoadjuvant setting (n ¼ 52). Expression was correlated with clinical-pathological parameters. Kaplan-Meier survival estimates revealed that expression of c-Myc, Ets-2 and SRC-1 individually all associated with a reduced period of disease-free survival (Po0.002, Po0.001 and Po0.001 respectively) (Figures 6a-c). There was no association found between expression of SRC-3 and disease-free survival (P ¼ 0.707) (Figure 6d ). Using the Fisher's exact test, Ets-2 expression correlated with that of c-Myc (Po0.0001) and SRC-1 (Po0.01) but not SRC-3 (P ¼ 0.752). Both c-Myc and Ets-2 were found to inversely associate with ER and positively with HER2 status, in addition Ets-2 correlated with ductal histology (Table 1 ). In this cohort of patients, we found no association between the expression of SRC-3 and any of the variables tested (Table 1) . There was no association between Ets-2, SRC-1, SRC-3 or c-Myc and response to chemotherapy.
Discussion
Increased significance of the growth factor/MAP kinase pathway in endocrine resistance has several consequences. Firstly, elevated crosstalk between growth factor and endocrine signalling mechanisms manifest by hyperactivation of the ER; secondly, the activation of MAP kinase effector transcription factors, resulting in regulation of target gene expression independently of steroid nuclear receptors. Many studies have suggested that the MAP kinase effectors, the Ets transcription factors are causally involved in breast cancer development and progression. Of interest, we have reported strong associations between Ets-1 and -2 and reduced disease-free survival in a cohort of breast cancer patients on adjuvant endocrine therapy (Myers et al., 2005) .
To investigate the molecular mechanisms involved in Ets mediated endocrine resistance we employed several cell line models which represent endocrine sensitive (MCF-7), endocrine independent but responsive (LCC1), endocrine resistant (LY2) and endocrine insensitive breast cancer cells (SKBR3). The growth factor EGF regulated levels of Ets-2 and c-Myc in both endocrine resistant and insensitive p160 proteins utilize Ets-2 in resistant breast cancer D Al-azawi et al cell lines, but not in the endocrine sensitive or endocrine independent/responsive breast cancer cells. This modulation of Ets-2 and c-Myc in the endocrine resistant and insensitive setting suggests a hyperactivated MAP kinase pathway may be important in disease progression and is consistent with the observation that c-Myc protein accumulation in human cancer results from ERKmediated stabilization and protein deregulation (Sears et al., 2000) .
The ability of Ets-2 to transcriptionally activate the myc promoter and regulate protein expression was examined. In endocrine insensitive SKBR3 cells, Ets-2 is recruited to the myc promoter in cells cultured in the presence of growth factors. In both the endocrine resistant and insensitive cell lines, treatment with growth factors and/or overexpression of Ets-2, but not Ets-1, resulted in heightened transcriptional activity and protein expression of the target gene. Increased myc promoter activity in the presence of exogenous Ets-2 was not observed in the tamoxifen sensitive MCF-7 cells. The inability of Ets-2 to induce a response from the reporter in the untreated MCF-7 cells is of significant interest and suggests that growth factor/ MAP kinase activation of Ets-2 is required for it to function at a transcriptional level. It is known that Ets-2 is a target for activated ERK1/2 and prolonged activation of MAP kinase leads to sustained phosphorylation of Ets-2 and subsequently to the stable induction of target genes (Sharrocks et al., 1997; Fowles et al., 1998) . These findings suggest that in endocrine resistant/ insensitive cells the dominant nature of the growth factor pathways result in higher basal levels of Ets-2 phosphorylation and hence transcriptional activation. To confirm functional significance of this MAP kinase mediated activation of Ets-2 transcriptional induction of myc we examined the effect of a threonine 72 to alanine mutation of the Ets-2 protein, a mutation which is known to impair Ras/MAP kinase induction of Ets-2 transcriptional activation (Yang et al., 1996) . We observed that wild type, but not the mutated form of Ets-2 could upregulate myc mRNA. Taken together, these data suggest that Ets-2, but not Ets-1, can transcriptionally regulate myc in the endocrine resistant/insensitive setting.
There is now evidence to support a role for the p160 and cointegrator proteins as functional coactivators of Ets transcription factors (Goel and Janknecht, 2004, Myers et al., 2005) . The p160 proteins independently associate with reduced disease-free survival on endocrine treatment and have been shown to be recruited to ERa in the presence of tamoxifen when under the influence of an activated HER2/MAP kinase system (McIlroy et al., 2006) . Molecular and clinical evidence suggests that crosstalk between ER and growth-factor pathways contribute to endocrine insensitivity, at least in part through phosphorylation and activation of the cointegrator proteins, CBP and p300 and the p160 proteins (Osborne et al., 2005) . Development of endocrine resistance and increased significance of growth factor pathways suggests that p160s may also utilize transcription factor hosts downstream of the MAP kinase pathway to mediate breast cancer cell survival. Here it was observed that when either p160 was silenced, in addition to decreased c-Myc protein expression there was concomitant loss of myc promoter activity suggesting that the coactivators can function as transcriptional regulators. Furthermore, knock down of SRC-1 or SRC-3 inhibited EGF-induced myc mRNA expression. Knock down of SRC-3 however also resulted in reduced Ets-2 protein levels, suggesting that SRC-3 may mediate its effects, at least in part, through the regulation of Ets-2 expression. Loss of myc transcriptional activity, due to knock down of SRC-1, was partially recovered in the endocrine insensitive cells on growth factor treatment. This may be due to the presence of elevated levels of endogenous Ets-2.
These molecular data indicate that Ets-2 in collaboration with the p160 proteins regulate c-Myc to promote the development of endocrine resistance. To establish the relevance of these findings in an ex vivo setting we examined a cohort of breast cancer patients with locally advanced disease. In a previous population of patients with primary breast cancer receiving endocrine therapy we found that expression of the p160 protein SRC-1, but Figure 2 Ets-2 transcriptional regulation of c-Myc expression. (a) Recruitment of Ets-2 to the myc promoter in response to treatment with growth factors. Breast cancer cells were treated for 4 h and subjected to chromatin immunoprecipitation (ChIP) analysis. The immunoprecipitates were performed with antibodies against Ets-2 (lanes 1-4), acetylated histone H4 (lanes 5 and 6) as positive control or no antibody (lane 7) as negative control. Human genomic DNA was used as a positive control (lane 8). The isolated promoter DNA fragments were amplified using a pair of primers covering the Ets-2 response element of the myc gene promoter. A set of primers amplifying a distal downstream region of the myc gene was used as control for the PCR (lanes 1 and 2) . Inputs represent soluble chromatin that was reverse crosslinked and amplified by PCR (30 cycles). (b) SKBR3 cells and (c) MCF-7, LY2 and SKBR3 cells were transfected with the pGL3 plasmid containing the Ets-2 response element (E2F) specific for the myc promoter, pGL3-myc promoter and the internal control vector pRL. The effect of epithelial growth factor (EGF) and/or exogenous expression of Ets-1 or -2 were observed by treating the cells with EGF (10 ng ml À1 ) for 4 h and/or co-transfection with either pCGN-Ets-1 or pCGN-Ets-2. Luciferase was measured using the dual luciferase reporter system and normalized to Renilla luciferase. Results are expressed as mean ± s. p160 proteins utilize Ets-2 in resistant breast cancer D Al-azawi et al not SRC-3, had a significant impact on Ets-2-associated disease recurrence (Myers et al., 2005) . As the relevance of Ets-mediated c-Myc signalling increased with the development of the cell model from endocrine sensitive to endocrine resistant through to endocrine insensitive, we chose to examine expression and coexpression of these proteins in a small select group of patients with locally advanced breast disease. As all patients were treated with both endocrine and chemotherapy treatments in a neoadjuvant setting, associations with molecular targets reflect both the prognostic and predictive properties of these markers. Ets-2 and c-Myc were all localized to the tumour epithelial cells, predominantly to the nucleus. In locally advanced breast cancer patients, Ets-2 expression was found to associate with both the coactivator SRC-1 and c-Myc, however, in line with our previous findings in primary breast tumours, no association was found between Ets-2 and SRC-3. Consistent with the importance of the growth factor/MAP kinase cascade in this proposed signalling pathway, Ets-2, SRC-1 and c-Myc all associated with expression of the growth factor receptor HER2. Expression of the transcription factor Ets-2, its coactivator SRC-1 and the target c-Myc all predicted time to disease recurrence which represents response to endocrine treatment rather than chemotherapy as there was no association between expression of any of the factors examined and response to chemotherapy. It is also noteworthy that both Ets-2 and c-Myc were found to associate positively with HER2 and inversely with ER status. This suggests that in a more aggressive breast cancer phenotype, typified by this patient cohort, we see a shift from steroid to growth factor regulation of classical ER target genes such as myc. In conclusion, we feel this molecular data, coupled with the clinical studies support the premise that combined growth factor/endocrine therapy, may be beneficial in breast cancer patients exhibiting this profile.
Materials and methods
Cell culture and cell treatments Breast cancer cell lines-endocrine-sensitive MCF7 (ATCC, LGC Promochem, Teddington, Middlesex, UK), endocrine independent/endocrine sensitive, MCF-7 derived LCC1 cells (Brunner et al., 1993) and endocrine-resistant, MCF7-derived LY2 (Bronzert et al., 1985) (kind gifts from Robert Clarke, Georgetown University, Washington DC)-were maintained in phenol red-free Eagle's minimum essential medium with 2 mM L-glutamine and supplemented with charcoal dextran stripped fetal bovine serum, 10% (Invitrogen, Paisley, UK). Endocrine-insensitive SKBR3 (ATCC) were maintained in RPMI medium with 2 mM L-glutamine and supplemented with fetal bovine serum, 10% (Invitrogen). All cell lines were incubated at 37 1C, under 5% CO 2 . Cells were serum starved for 24 h prior to treatment with EGF (10 ng ml À1 ; SigmaAldrich, Poole, UK) over varying time periods.
Western blotting
Protein samples (50 mg) were electrophoresed and transferred to nitrocellulose membrane (BioRad, Herts, UK; n ¼ 3). The p160 proteins utilize Ets-2 in resistant breast cancer D Al-azawi et al membrane was blocked (5% nonfat milk), and incubated with rabbit anti-human Ets-1 (2 mg ml
À1
; sc-350, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), rabbit anti-human Ets-2 (2 mg ml
; sc-351, Santa Cruz), rabbit anti-human SRC-1 (2 mg ml
; sc-8995, Santa Cruz), rabbit anti-human SRC-3 (2 mg ml
; sc-13066, Santa Cruz) or rabbit anti-human c-Myc (sc-788, Santa Cruz) followed by corresponding horseradish peroxidase-conjugated secondary antibodies (Santa Cruz; 1:7500). Equal protein loading was confirmed by blotting for b-actin (Sigma-Aldrich). Densitometry was conducted using the AlphaEase FC software (Alpha Innotech) and normalized to actin.
Chromatin Immunoprecipitation (ChIP) SK-BR-3 cells were treated with EGF for 4 h and ChIP was performed as previously described (Cosgrave et al., 2006) . Rabbit anti-human Ets-2 (6 mg) (Santa Cruz) or H4 antibody (5 ml) (positive control) were added to the supernatant fraction and incubated overnight at 4 1C with rotation. Primers were designed from the myc promoter (accession number: X00364) using Oligoperfect software (www.invitrogen.com); forward primer-TTTATAATGCGAGGGTCTGGACGGCTGA, reverse primer-ATCCCTCCCTCCGTTCTTT. Control primers were designed upstream of the myc promoter in a region lacking an Ets response element; forward primer-GACCAGCTGGA GATGGTGAC, reverse primer-GCTGTCGTTGAGAGGG TAGG.
Ets response element inserts for pGL3 promoter luciferase vector An Ets response element, E2F, as previously described on the myc promoter (X00364) (Roussel et al., 1994) was located using Genomatix MatInspector (http://www.genomatix.de). A DNA sequence specific for the myc promoter and containing the Ets transcription factor binding site was designed (forward strand-CTAGAGGGCAGGGCTTCTCAGAGGCTTGGC GGGAAAAAGAACGGAGGGAGGGATCGCGC; reverse strand-GATCGCGCGATCCCTCCCTCCGTTCTTTTTCC CGCCAAGCCTCTGAGAAGCCCTGCCCT) and cloned into the pGL3 reporter vector supplied in the Dual-reporter Luciferase kit (Pierce Biotechnology Inc., Rockford, IL, USA).
Luciferase assay protocol
Control reporter vector (pRL) was cotransfected to provide low-level, constitutive expression of Renilla luciferase activity. A total of 0.5 Â 10 6 cells were cultured in six-well plates in antibiotic-free, serum-enriched media for 24 h. Cells were transfected with pGL3 vector (1 mg) or pGL3-myc promoter (1 mg), pRL (100 ng) and pGCN-Ets-2 expression vector 
Ets-2 overexpression studies
The Ets-2 expression vector (pCGN-Ets-2) and the mutant PCGN-Ets-2(T72A) vector were a gift from Dr Toshihiko Ezashi, University of Missouri-Columbia, Columbia, MO, USA (Yang et al., 1996) . Cells were transfected using Lipofectamine 2000 transfection reagent (Invitrogen), incubated at 37 1C for 24 h after which time full media was added with or without EGF (10 ng ml À1 ; Sigma-Aldrich) for 24 h and protein extracted as previously described (Cosgrave et al., 2006) . RNA was harvested, reverse transcribed and the following primers used for PCR: Ets-2 forward, GCAAGGCTGTGATGACTGAA; Ets-2 reverse, CCCTGC AGATTCACGTTCA; myc forward, TTCGGGTAGTGGAA AACCAG; myc reverse, CAGCAGCTCGAATTTCTTCC; b-actin forward, TCACCCACACTGTGCCCATCTACGA; b-actin reverse, CAGCGGAACCGCTCATTGCCAATGG.
Downregulation of SRC-1 and SRC-3 using siRNA Pre-designed siRNA directed against SRC-1 (Ambion, Oxford, UK, Cat no. 115458) and Ets-2 (Invitrogen, Cat no. 1299003) were used to knockdown expression. siRNA-SRC-3 was constructed and these genes were silenced as previously described (McIlroy et al., 2006) .
Apoptosis-acridine orange/ethidium bromide staining LY2 and SKBR3 cells were stained with acridine orange (50 mg ml
À1
) and ethidium bromide (50 mg ml À1 ) and visualized using a fluorescein isothiocyanate (FITC) filter. Apoptotic cells were identified by characteristic nuclear changes and apoptotic body formation as previously described (Duke et al., 1994) .
Immunohistochemistry
Ets-2, SRC-1, SRC-3 and c-Myc were detected within archival paraffin-embedded breast tumour specimens. Sections were incubated with rabbit anti-human Ets-2 (1 mg ml À1 ) (sc-351, Santa Cruz), rabbit anti-human SRC-1 (2 mg ml À1 ) (sc-8995, Santa Cruz), rabbit anti-human SRC-3 (2 mg ml À1 ) (sc-13066, Santa Cruz) and mouse anti-human c-Myc (2 mg ml À1 ) (sc-40, Santa Cruz) followed by corresponding biotin-labelled secondary antibody (1:2000) using the Vectastain Elite kit (Vector Labs, Burlingame, CA, USA) according to the manufacturer's instructions. Staining was assessed as previously described (Myers et al., 2005) .
Immunofluorescent microscopy
Breast cancer sections were blocked in goat serum, incubated with rabbit anti-human Ets-2 (10 mg ml À1 in 10% human serum; sc-351, Santa Cruz) followed by TRITC conjugated goat anti-rabbit secondary antibody (1:100) (Sigma-Aldrich). Sections were co-incubated with mouse anti-human c-Myc (10 mg ml À1 in 10% human serum) followed by FITCconjugated sheep anti-mouse secondary antibody (1:100) (Sigma-Aldrich, Steinheim, Germany). Slides were mounted using fluorescent mounting media (DAKO, Glostrup, Denmark).
Clinical-pathological parameters
Following ethical approval, 52 patients with locally advanced breast cancer were included in the study; patients were diagnosed between 1999 and 2004 by core biopsy or FNAC (Fine needle aspiration cytology). Patients were treated with neoadjuvant hormonal therapy and chemotherapy prior to surgery. All patients had stage I-II breast cancer at presentation and were assessed by abdominal ultrasound, chest X-ray and bone scintigraphy before surgery. HER2 status was evaluated using the DAKO HercepTest immunocytochemical assay (DAKO). Variables analysed include tumour size, tumour grade, tumour stage, ER status, HER2/neu receptor status. Histological grading was performed by a pathologist using the Eliston-modified Scarff-Bloom-Richardson system (Elston and Ellis, 1991) . All patients underwent total or segmental mastectomy with level I, II and III axillary dissection. Time to disease progression was defined as the period from the initiation of treatment to the time of disease recurrence or death. Response to primary chemotherapy was assessed using Chevallier's classification (Chevallier et al., 1993) .
Statistical analysis SAS version 8.2 statistical program (SAS Institute, Cary, NC, USA) was used in the statistical analysis. Univariate analysis was performed using Fisher's exact test for categorical variables and Wilcoxon's test for continuous variables. Multivariate analysis was carried out using Cox's proportional hazard model. A P-value of less than 0.05 was considered to be significant. Survival times between groups were compared using the Wilcoxon's test adjusted for censored values.
